The results of the EINSTEIN-DVT study, announced on August 31 at the European Society of Cardiology, demonstrated that rivaroxaban (Xarelto, Bayer, Johnson & Johnson) , an oral anti-Xa anticoagulant is as effective and safe as warfarin in treating acute deep venous thrombosis. Xarelto was released for prophylaxis in Northern Europe and Canada in the spring of 2009, and is currently in FDA review. The release from the ESC meeting includes summary information on all the new oral anticoagulant drugs in trials.
Sep 10 2010
No comments here.